ClinicalTrials.gg
CompletedNCT07420582Updated Oct 21, 2026

Antegrade Autologous Blood Reinfusion After CPB

An observational study in Coronary Artery Disease, sponsored by Kocaeli City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Kocaeli City Hospital · Observational

How we know

Updated Oct 21, 2026Now CompletedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Coronary Artery Disease with a site in Turkey — 34 open to participants now, 43 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.

Enrollment
38th of 66
130 · median 167
Started
2026
with 25 others
Observational
66 of 139
15 open now
Registered
110th of 139
by date

Among the 139 studies in Coronary Artery Disease with a site in Turkey, this one is the 38th largest by enrollment of the 66 observational ones that give a count, is one of 26 that started in 2026, is one of 66 observational ones, and was the 110th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

34 of the 139 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Coronary Artery Disease with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adult patients (18-80 years) scheduled for elective, primary isolated coronary artery bypass grafting (CABG) using cardiopulmonary bypass at Kocaeli City Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years
  • Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).

Exclusion criteria

Exclusion Criteria:

  • Emergency or Redo cardiac surgery
  • Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
  • Planned or intraoperative conversion to off-pump coronary artery bypass grafting
  • Preoperative hematocrit \<30% or known inherited/acquired bleeding disorders.
  • Preoperative \<30%.
  • Thrombocytopenia (e.g., count \<100×10³/µL) or abnormal coagulation tests.
  • Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
  • Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
  • Use of any intraoperative allogeneic blood product (red blood cells, fresh frozen plasma, or platelets)
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
  • Severe renal dysfunction ( \<30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction ( B-C or coagulopathy).
  • Active infection or systemic inflammatory/ disease.
  • Active requiring ongoing treatment
  • Refusal or inability to provide written .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (actual)
Patient registry
No

Groups and cohorts

  • Antegrade Pump Blood Reinfusion (Chase Technique)

    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.

    Procedure: Antegrade Pump Blood Reinfusion

  • No Pump Blood Reinfusion

    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is not performed at the end of bypass, and standard clinical management is applied.

    Other: No Anterograde Pump Blood Reinfusion

Interventions

  • ProcedureAntegrade Pump Blood Reinfusion

    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.

  • OtherNo Anterograde Pump Blood Reinfusion

    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom anterograde pump blood reinfusion is not performed at the end of bypass. Standard institutional clinical management is applied.

06

What researchers measure

Primary outcomes

  1. Postoperative Blood Transfusion Requirement

    Incidence of allogeneic blood transfusion within the first 24 hours after surgery.

    Time frame: From the end of surgery to 24 hours postoperatively

Secondary outcomes

  1. Postoperative Drainage Volume

    Total postoperative chest drainage volume within the first 24 hours after surgery.

    Time frame: From the end of surgery to 24 hours postoperatively

07

Study locations

1 site
  • Kocaeli City Hospital
    Kocaeli, Izmit, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Aug 2026, 5 months.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 5 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Feb 23, 2026
Primary completionActual
Aug 11, 2026was Jun 2026
CompletionActual
Aug 18, 2026was Jun 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 20, 2026
Primary completion
Jun 1, 2026→Aug 11, 2026 (actual)
Oct 20, 2026
Study completion
Jun 15, 2026→Aug 18, 2026 (actual)
Oct 20, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedUse of any intraoperative allogeneic blood product (red blood cells, fresh frozen plasma, or platelets)
Oct 21, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedNumber of Transfused Blood UnitsTime frame: From the end of surgery to 24 hours postoperatively
Oct 20, 2026
Show all 2 updates
  1. Oct 21, 2026
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedUse of any intraoperative allogeneic blood product (red blood cells, fresh frozen plasma, or platelets)
  2. Oct 20, 2026
    Recruiting→Completed
    Primary completion Jun 1, 2026→Aug 11, 2026 (now actual)
    Study completion Jun 15, 2026→Aug 18, 2026 (now actual)
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedNumber of Transfused Blood UnitsTime frame: From the end of surgery to 24 hours postoperatively
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07420582
Lead sponsor
Kocaeli City Hospital
Responsible party
Zeynep Yasemin Tavşanoğlu (Principal Investigator, Medical Doctor, Kocaeli City Hospital) — Principal investigator
First posted
Feb 19, 2026
Start date
Feb 23, 2026
Primary completion
Aug 11, 2026
Completion
Aug 18, 2026
Last update
Oct 21, 2026

Study contacts

Zeynep Yasemin Tavsanoglu, MD
principal investigator · Kocaeli City Hospital, Department of Anesthesiology and Reanimation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion